GenoCap Bio Secures Over RMB 100 Million Series A Funding Led by Huiyuan Capital to Accelerate Microchamber Chip-Based Digital PCR Development

VCBeat (WeChat ID: vcbeat) has learned that ZIZBO Biotechnology (Shanghai) Co., Ltd. (“ZIZBO”), a leading enterprise in digital PCR, recently completed its Series A financing round of over RMB 100 million, with exclusive investment from Grand Mount Capital, a professional healthcare-focused investment firm. By leveraging its extensive industry resources, Grand Mount Capital will empower ZIZBO to accelerate the adoption and promotion of digital PCR in life sciences and clinical applications. The proceeds from this round will be allocated toward the clinical registration, market promotion, and scaled manufacturing of microchamber chip-based digital PCR products, as well as the research and development of multiple assay kit products.

Digital PCR technology is hailed as the "third-generation PCR technology." Compared to traditional real-time fluorescence PCR, digital PCR enables absolute quantification of nucleic acid copy numbers, with a detection sensitivity as high as 0.01%, offering broad application prospects. After more than a decade of development, among various technical approaches, "microchamber chip-based" technology has gradually become the mainstream route for digital PCR due to its superior uniformity, stability, and efficiency, and is also the technical direction chosen by many international giants.

ZIZBO, founded in 2016 and headquartered in Shanghai, has established R&D and production centers across China and is a domestic leader in microcavity chip-based digital PCR technology. The company’s team comprises professionals from renowned multinational corporations and research institutions, bringing extensive R&D and industrialization expertise in core areas such as micro-nano fabrication, precision instrumentation, biological reagents, clinical applications, and software algorithms. ZIZBO has overcome technical challenges in microcavity chip manufacturing and surface treatment processes, successfully achieving low-cost, large-scale production.

The company has established five core technology platforms with independent intellectual property rights, covering micro-nano biochips, automated medical equipment, microscopic biological fluorescence imaging, AI image algorithms, and IVD diagnostic reagents, providing a solid technical foundation for production and R&D. As the only domestic enterprise mastering diversified digital PCR product solutions, ZIZBO has collaborated with over one hundred institutions across industries such as scientific research, IVD, biopharmaceuticals, and inspection and quarantine. To meet customer needs in different application scenarios, the company has developed instruments, chips, and kit products in various specifications. The company’s first domestically launched microcavity chip-based digital PCR system has obtained the NMPA medical device registration certificate, and its high-throughput 6-color fluorescence digital PCR system, which was launched ahead of competitors, addresses the limitations of similar global products in multiplex fluorescence detection capabilities.

Zhang Shanshan, Founding Partner of Grand Mount Capitalstated: “Our team has been tracking the digital PCR sector for several years, and we firmly believe in the development potential and performance advantages of microcavity chip-based technology in the field of digital PCR. We are delighted to see that ZIZBO’s products not only match the performance of imported counterparts but also significantly reduce costs. Its product portfolio closely aligns with market demands and is highly competitive. Through this equity investment, we will leverage the high-quality resources of industrial investors in the healthcare sector to deeply empower ZIZBO, connect it with distribution channels spanning thousands of hospitals, provide scalable production capabilities, and jointly develop diagnostic products urgently needed in clinical settings. This will further expand the company’s leading position in the industry and explore greater possibilities across additional business areas.”

Guo Feng, Chairman of ZIZBOstated: “ZIZBO has built a highly efficient and professional core team, adhering to a long-termism approach by diligently developing products that truly meet market demands and align with clinical needs. As a professional investment institution with abundant industry resources, Grand Mount Capital will provide dual support in funding and industrial resources, which will undoubtedly accelerate our journey to becoming a globally leading digital PCR enterprise. Following this collaboration, we will further expedite product manufacturing and reagent R&D, complete our layout across clinical, scientific research, and industrial markets, build a digital PCR ecosystem, popularize digital PCR technology, and fully realize its social value. ZIZBO will continue to uphold its corporate vision of ‘making testing simpler,’ striving to create a world-class in vitro diagnostics platform, safeguarding human health, and advancing life exploration!”

ZIZBO, established in 2016, is dedicated to the R&D, production, sales, and services of life science technologies and in vitro diagnostic (IVD) products. The company has launched its digitally PCR-based product with independent intellectual property rights, which enables absolute quantification of nucleic acid molecules with ultra-high sensitivity. This technology holds broad application prospects in fields such as liquid biopsy for tumor genes, non-invasive prenatal testing (NIPT), pathogenic microorganism detection, gene therapy, and gene editing. Centered on this product, ZIZBO provides a range of services including technical collaborations, product development, standard establishment, and sample testing.

Huiyuan Capital, established in 2019, is a professional healthcare investment firm focused on value investing in the biopharmaceutical and medical device sectors. Controlled and operated by a market-oriented professional team, it was jointly initiated with state-owned strategic shareholders. The firm systematically invests in high-quality targets possessing breakthrough and innovative technologies within niche segments, has established in-depth collaborative relationships with multiple industry players, and adheres to an investment strategy of “industry empowerment + capital support,” aiming to deliver long-term, stable investment returns to its investors.